[go: up one dir, main page]

AU2001288724A1 - Dihydroxy open-acid salt of simvastatin - Google Patents

Dihydroxy open-acid salt of simvastatin

Info

Publication number
AU2001288724A1
AU2001288724A1 AU2001288724A AU8872401A AU2001288724A1 AU 2001288724 A1 AU2001288724 A1 AU 2001288724A1 AU 2001288724 A AU2001288724 A AU 2001288724A AU 8872401 A AU8872401 A AU 8872401A AU 2001288724 A1 AU2001288724 A1 AU 2001288724A1
Authority
AU
Australia
Prior art keywords
compound
differential scanning
scanning calorimetry
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288724A
Other languages
English (en)
Inventor
Edward J. J. Grabaowski
Paul J. Reider
Richard D Tillyer
Richard J. Varsolona
Jose M. Vega
Robert M. Wenslow
Feng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2001288724A1 publication Critical patent/AU2001288724A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2001288724A 2000-09-06 2001-09-05 Dihydroxy open-acid salt of simvastatin Abandoned AU2001288724A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65610900A 2000-09-06 2000-09-06
US09656109 2000-09-06
US66095600A 2000-09-13 2000-09-13
US09660956 2000-09-13
PCT/US2001/027466 WO2002020457A1 (fr) 2000-09-06 2001-09-05 Sel d'acide ouvert dihydroxy de simvastatine

Publications (1)

Publication Number Publication Date
AU2001288724A1 true AU2001288724A1 (en) 2002-03-22

Family

ID=27097115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288724A Abandoned AU2001288724A1 (en) 2000-09-06 2001-09-05 Dihydroxy open-acid salt of simvastatin

Country Status (6)

Country Link
US (2) US20030176501A1 (fr)
EP (1) EP1324972A4 (fr)
JP (1) JP2004508347A (fr)
AU (1) AU2001288724A1 (fr)
CA (1) CA2421018A1 (fr)
WO (1) WO2002020457A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479005C (fr) * 2002-03-18 2012-05-22 Biocon Limited Inhibiteurs de hmg-coa reductase amorphe avec taille souhaitee des particules
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP2006501205A (ja) * 2002-07-30 2006-01-12 カリキオン インコーポレイテッド エゼチミブ組成物、並びにコレステロールに関連した良性および悪性の腫瘍を治療する方法
WO2004071456A2 (fr) 2003-02-11 2004-08-26 Plus Chemicals, B.V. Procede de preparation de simvastatine ayant des gammes regulees de contenu de dimere de simvastatine
CN1795165A (zh) * 2003-04-01 2006-06-28 普拉斯化学品有限公司 无定形辛伐他汀钙及其制备方法
CA2543596A1 (fr) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Complexes pour une therapie combinatoire stimulant les hdl
US9499621B2 (en) 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
CN113135823A (zh) * 2021-04-27 2021-07-20 华南农业大学 一种辛伐他汀半抗原、人工抗原和抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES493726A0 (es) * 1979-07-27 1981-06-16 Sankyo Co Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos.
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
EP1163203A1 (fr) * 1999-03-08 2001-12-19 Merck & Co., Inc. Sel de calcium hydrate et cristallin de simvastatine d'acide ouvert en dihydroxy
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
JP2004508347A (ja) 2004-03-18
EP1324972A4 (fr) 2004-06-30
WO2002020457A1 (fr) 2002-03-14
US20050119343A1 (en) 2005-06-02
EP1324972A1 (fr) 2003-07-09
US20030176501A1 (en) 2003-09-18
CA2421018A1 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
US6569461B1 (en) Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU764048B2 (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
CA2364253A1 (fr) Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
EP1036563A1 (fr) Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
CN1867322B (zh) 结晶形式的γ-氨基丁酸类似物
KR20070092993A (ko) 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
US20030176501A1 (en) Dihydroxy open-acid salt of simvastatin
JP2009503119A (ja) （３ｒ，４ｓ）−４−（４−ヒドロキシ保護−フェニル）−１−（４−フルオロフェニル）−３−［３−（４−フルオロフェニル）−３−オキソプロピル］アゼチジン−２−オンを精製する方法
US20110111059A1 (en) Compositions Comprising Quinazoline Derivatives, Preparation Methods and Uses Thereof
CN113214209A (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
HK1029758A (en) Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
HK1029786A (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
SK10622002A3 (sk) Étery dikarboxylátu vápenatého, metódy ich výroby a ich využitie na liečbu vaskulárnych chorôb a diabetu
TW200835691A (en) Motilide polymorphs
ES2281594T3 (es) Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre.
EP1641447B1 (fr) Procede de purification de pravastatine
CA2595635A1 (fr) Procedes de fabrication de sodium de pravastatine
CN101973922B (zh) 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
MX2007000715A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
HK1090850B (en) Crystalline form of gamma-aminobutyric acid analog

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application